摘要
目的系统评价阿德福韦酯联合扶正化瘀胶囊(ADF+FC)及单用阿德福韦酯(ADF)治疗慢性乙型肝炎的有效性与安全性。方法计算机检索CNKI、万方数据库、PubMed、CBM、Medline、Web of Knowledge以及Elsevier数据库,检索时间均为从建库至2012年11月。2名研究者独立选择试验、质量评价及提取资料,采用RevMan4.3.2软件进行Meta分析。结果最终纳入5个随机对照试验(RCT),共455例患者。Meta分析结果显示:Ⅲ型原胶原比较,联合组优于单用组(SMD=-0.98,95%CI(-1.26,-0.71));层黏蛋白比较,联合组优于单用组(SMD=-0.69,95%CI(-0.88,-0.50));Ⅳ型胶原比较,联合组优于单用组(SMD=-0.50,95%CI(-0.93,-0.07));天门冬氨酸氨基转移酶比较,联合组优于单用组(SMD=-0.69,95%CI(-0.97,-0.41));门静脉直径比较,联合组优于单用组(SMD=-0.50,95%CI(-0.74,-0.26))。结论阿德福韦酯联合扶正化瘀胶囊治疗慢性乙型肝炎效果优于单用阿德福韦酯,但受纳入文献的数量和质量限制,以上结论需高质量大范围的临床试验进一步认证。
Objective It is to system assessment the effciacy and safety of adefovir dipivoxil （ADF） and Fuzhenghuayu capsule combined with adefovir dipivoxil （ ADF ＋ FC） in chronic hepatitis B （CHB）. Methods Such databases as CNKI, Wangfang Datebase, PubMed, CBM, Medline, Web of Knowledge and Elsevier were searched from the date of their establishment to Novemvber, 2012. RCT selection, methodological quaility accessment and data extration were conducted by two re- searchers independently. Meta analysis was done by RevMan V4.3.2. Results Five RCTs involving 455 patients were included. Meta analysis showed that： ADF＋FC group was superior than ADF group （SMD= -0.69, 95%CI（ -0.88, -0.50）） in comparison of PCII ; ADF ＋ FC group was superior than ADF group （ SMD = -0.69, 95% CI（ -0.88, -0.50） ） in com- parison ofLN; ADF＋FC group was superior than ADF group （SMD= -0.50, 95%CI（ -0.93, -0.07）） in comparison of IV - C; ADF ＋ FC group was superior than ADF group （SMD = -0.69, 95% CI（ -0.97, -0.41） ） in comparison of AST; ADF ＋ FC group was superior than ADF group （ SMD = - 0.50, 95% CI（ - 0.74, - 0.26） ） in comparison of protal vein diameter. Conclusion ADF ＋ FC is superior than ADF in treatment of CHB. However, limited by quality and quantity of included RCTs, it remains to be verified by high-quality and large-scale RCTs.
出处
《现代中西医结合杂志》
CAS
2014年第6期580-582,587,共4页
Modern Journal of Integrated Traditional Chinese and Western Medicine
